Factor | No. cases | Disease-specific survival HR (95% CI)a | P | Overall survival HR (95% CI)a | P |
---|---|---|---|---|---|
Gender | Â | Â | Â | Â | Â |
male | 65 | 1 | Â | 1 | Â |
female | 47 | 0.93 (0.38-2.28) | 0.880 | 1.65 (0.79-3.45) | 0.179 |
Age (years) | Â | Â | Â | Â | Â |
≤64 | 57 | 1 |  | 1 |  |
>64 | 55 | 2.31 (0.89-5.99) | 0.085 | 2.52 (1.26-5.07) | 0.009 |
Tumour stage | Â | Â | Â | Â | Â |
pT1+2 | 87 | 1 | Â | 1 | Â |
pT3+4 | 25 | 1.85 (0.73-4.69) | 0.192 | 1.17 (0.56-2.44) | 0.670 |
Tumour grade | Â | Â | Â | Â | Â |
G1+2 | 68 | 1 | Â | 1 | Â |
G3+4 | 44 | 2.08 (0.83-5.19) | 0.118 | 1.61 (0.82-3.14) | 0.165 |
uPA b | Â | Â | Â | Â | Â |
low | 53 | 1 | Â | 1 | Â |
high | 59 | 2.86 (1.07-7.67) | 0.037 | 1.28 (0.66-2.51) | 0.467 |
uPAR b | Â | Â | Â | Â | Â |
low | 55 | 1 | Â | 1 | Â |
high | 57 | 4.70 (1.51-14.6) | 0.008 | 1.60 (0.80-3.23) | 0.185 |
PAI-1 b | Â | Â | Â | Â | Â |
low | 56 | 1 | Â | 1 | Â |
high | 56 | 2.59 (0.95-7.08) | 0.064 | 1.71 (0.85-3.46) | 0.135 |